Insulet (PODD) Cash from Investing Activities (2010 - 2026)
Insulet's (PODD) quarterly Cash from Investing Activities came in at -$27.7 million in Q1 2026, down 77.56% YoY from -$123.5 million in Q1 2025, and up 81.87% on a QoQ basis from -$152.8 million in Q4 2025.
Insulet (PODD) Cash from Investing Activities (2010 - 2026) Analysis & Trends
Insulet (PODD) has 17 years of Cash from Investing Activities data on file, last reported at -$27.7 million in Q1 2026.
- Quarterly Cash from Investing Activities fell 77.56% year-over-year to -$27.7 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$234.8 million (down 70.39% YoY) and the FY2025 annual result came in at -$222.7 million, down 52.33% from the prior year.
- Cash from Investing Activities grew to -$27.7 million in Q1 2026, from -$152.8 million in the prior quarter.
- In the past five years, Cash from Investing Activities ranged from a high of -$15.6 million in Q1 2025 to a low of -$152.8 million in Q4 2025.
- A 5-year average of -$41.6 million and a median of -$29.3 million in 2024 frame the typical range for Cash from Investing Activities.
- Annual changes were most pronounced in 2022 — Cash from Investing Activities slumped 177.87% — and 2023, when it soared 64.25%.
- Tracing PODD's Cash from Investing Activities over 5 years: stood at -$88.4 million in 2022, then soared by 64.25% to -$31.6 million in 2023, then sank by 115.19% to -$68.0 million in 2024, then slumped by 124.71% to -$152.8 million in 2025, then soared by 81.87% to -$27.7 million in 2026.
- The last three Cash from Investing Activities figures came in at -$27.7 million (Q1 2026), -$152.8 million (Q4 2025), and -$31.0 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Investing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 202.72 Bn | 197.12 Bn | 7.27 Bn | -673.00 Mn |
| 2 | Stryker | 126.42 Bn | 122.94 Bn | 4.50 Bn | -639.00 Mn |
| 3 | Medtronic | 119.75 Bn | 110.53 Bn | 6.41 Bn | -917.00 Mn |
| 4 | Boston Scientific | 74.13 Bn | 73.60 Bn | 3.85 Bn | -1.96 Bn |
| 5 | Edwards Lifesciences | 51.78 Bn | 47.53 Bn | 1.35 Bn | -193.20 Mn |
| 6 | Dexcom | 35.29 Bn | 33.34 Bn | 830.00 Mn | 329.80 Mn |
| 7 | GE HealthCare Technologies | 33.95 Bn | 31.85 Bn | 2.18 Bn | -115.00 Mn |
| 8 | Koninklijke Philips | 26.22 Bn | 22.90 Bn | 4.55 Bn | -22.08 Mn |
| 9 | Steris | 23.21 Bn | 22.73 Bn | 684.20 Mn | -108.50 Mn |
| 10 | Insulet | 10.27 Bn | 9.74 Bn | 562.60 Mn | -37.40 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -37.40 Mn |
| Jun 30, 2026 | -37.40 Mn |
| Mar 31, 2026 | -27.70 Mn |
| Mar 31, 2026 | -27.70 Mn |
| Dec 31, 2025 | -152.80 Mn |
| Dec 31, 2025 | -152.80 Mn |
| Sep 30, 2025 | -31.00 Mn |
| Sep 30, 2025 | -31.00 Mn |
| Jun 30, 2025 | -23.30 Mn |
| Jun 30, 2025 | -23.30 Mn |
| Mar 31, 2025 | -15.60 Mn |
| Mar 31, 2025 | -15.60 Mn |
| Dec 31, 2024 | -68.00 Mn |
| Dec 31, 2024 | -68.00 Mn |
| Sep 30, 2024 | -29.30 Mn |
| Sep 30, 2024 | -29.30 Mn |
| Jun 30, 2024 | -24.90 Mn |
| Jun 30, 2024 | -24.90 Mn |
| Mar 31, 2024 | -24.00 Mn |
| Mar 31, 2024 | -24.00 Mn |